Abstract:PGAP2 gene has been known to be the cause of "hyperphosphatasia, mental retardation syndrome-3" (HPMRS3). To date, 14 pathogenic variants in PGAP2 have been identified as the cause of this syndrome in 24 patients described in single-case reports or small clinical series with pan-ethnic distribution. We aim to present a pediatric PGAP2 -mutated case, intending to further expand the clinical phenotype of the syndrome and to report our experience on a therapeutic approach to drug-resistant epilepsy. We present the clinical, neuroradiological, and genetic characterization of a Caucasian pediatric subject with biallelic pathogenic variants in the PGAP2 gene revealed by next generation sequencing analysis. We identified a subject who presented with global developmental delay and visual impairment. Brain magnetic resonance imaging showed mild hypoplasia of the inferior cerebellar vermis and corpus callosum and mild white matter reduction. Laboratory investigations detected an increase in alkaline phosphatase. At the age of 13 months, he began to present epileptic focal seizures with impaired awareness, which did not respond to various antiseizure medications. Electroencephalogram (EEG) showed progressive background activity disorganization and multifocal epileptic abnormalities. Treatment with high-dose pyridoxine showed partial benefit, but the persistence of seizures and the lack of EEG amelioration prompted us to introduce ketogenic diet treatment. Our case provides a further phenotypical expansion of HPMRS3 to include developmental and epileptic encephalopathy. Due to the limited number of patients reported so far, the full delineation of the clinical spectrum of HPMRS3 and indications for precision medicine would benefit from the description of new cases and their follow-up evaluations. Ethics committee approval is not required because genetic analyses are only for clinical diagnosis. Consent from patients and parents was obtained to publish detailed medical histories of patients. A.S., M.T., C.V., and S.O. were responsible for the conception and design of the paper; A.S., M.T., C.V., and S.O. wrote the original draft of the paper; S.G., M.P., E.R., G.P., and V.D.G. analyzed data. All authors contributed to the writing of the final manuscript. V.D.G. received research fundings and speaker fees from Eisai srl, GW Pharmaceuticals, Neu-raxpharm, Nutricia, Kanso, and Nestlè. V.D.G., S.G., A.P., M.P., E.R., C.V., and S.O. received financial support from the Italian Ministry of Health (RC 2022-2024) for the IRCCS Mondino Foundation in Pavia, Italy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. * Drs Saracino and Totaro equally contributed to this investigation (co-first authors) Received: 29 September 2023 Accepted: 02 January 2024 Article published online: 16 February 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Biallelic variants in GTPBP3: New patients, phenotypic spectrum, and outcome

Pathogenicity Analysis of a Novel Variant in GTPBP3 Causing Mitochondrial Disease and Systematic Literature Review

Novel Mutations in the GTPBP3 Gene for Mitochondrial Disease and Characteristics of Related Phenotypic Spectrum: The First Three Cases From China

Alternating Hemiplegia and Epilepsia Partialis Continua: A new phenotype for a novel compound TBC1D24 mutation

Mutations in GTPBP3 cause a mitochondrial translation defect associated with hypertrophic cardiomyopathy, lactic acidosis, and encephalopathy

Biallelic variants in cause a mitochondrial disorder primarily manifesting as peripheral neuropathy

Biallelic variant in AGTPBP1 causes infantile lower motor neuron degeneration and cerebellar atrophy

Further Clinical Delineation of Prolidase Deficiency Associated with c.1103T>G Variant

Severe phenotypes of B3GAT3-related disorder caused by two heterozygous variants: a case report and literature review

The neurological core features of the infantile‐onset multisystem neurologic, endocrine, and pancreatic disease: A novel nonsense mutation in an Italian family

POLG1 mutations manifesting as autosomal recessive axonal Charcot-Marie-Tooth disease.

Two novel POLG mutations causing hepatic mitochondrial DNA depletion with recurrent hypoketotic hypoglycaemia and fatal liver dysfunction

Consolidating the Role of Mutated ATP2B2 in Neurodevelopmental and Cerebellar Pathologies

Familial childhood onset, slowly progressive myopathy plus cardiomyopathy expands the phenotype related to variants in the TTN gene

Biallelic variants in COX18 cause a mitochondrial disorder primarily manifesting as peripheral neuropathy

Defining the phenotype of PGAP3-congenital disorder of glycosylation; a review of 65 cases

Case report: Novel compound heterozygosity for pathogenic variants in MED23 in a syndromic patient with postnatal microcephaly

A novel frameshift TBX4 variant in a family with ischio-coxo-podo-patellar syndrome and variable severity

PGAP2-Related Hyperphosphatasia-Mental Retardation Syndrome: Report of a Novel Patient, Toward a Broadening of Phenotypic Spectrum and Therapeutic Perspectives

IGHMBP2 -Related Clinical and Genetic Features in a Cohort of Chinese Charcot–Marie–Tooth Disease Type 2 Patients

A Novel GBF1 Variant in a Charcot-Marie-Tooth Type 2: Insights from Familial Analysis